摘要
目的 探讨OTUD6B在肺腺癌(lung adenocarcinoma, LUAD)组织中的表达情况,分析其与患者临床病理特征的关系及预后价值。方法 从TCGA数据库下载LUAD患者的测序数据及临床信息,分析OTUD6B与LUAD患者临床病理特征的相关性,通过Kaplan-Meier方法比较OTUD6B高表达与低表达两组患者的OS差异,采用单因素和多因素Cox回归分析影响患者总生存期(Overall survival, OS)的独立预后因素。通过WB及RT-qPCR检测正常人支气管上皮细胞系BEAS-2B和人肺腺癌细胞系A549中OTUD6B表达情况,并在A549中敲低OTUD6B后通过CCK8检测对细胞增殖的影响。结果 OTUD6B在肺腺癌组织中的表达明显高于癌旁组织,差异具有统计学意义(t=13.056,P<0.001);并且在配对的癌与癌旁组织中也存在同样差异(t=2.744,P=0.008)。不同性别、年龄、吸烟与否的LUAD患者肿瘤组织中OTUD6B的表达差异均无统计学意义(P均>0.05);而病理分期Ⅲ-Ⅳ期患者较Ⅰ-Ⅱ期患者肿瘤组织中OTUD6B的表达水平显著升高,差异具有统计学意义(P<0.05)。远期预后方面,OTUD6B高表达组的中位OS为42.39个月,显著低于低表达组的58.30个月,差异具有统计学意义(HR=1.500,95%CI=1.124~2.003,P=0.006)。OTUD6B表达水平是影响患者OS的独立危险因素(P=0.014)。A549细胞系中OTUD6B mRNA及蛋白表达水平均高于BEAS-2B细胞,且在A549中敲低OTUD6B后,细胞增殖能力显著下降。结论 OTUD6B在LUAD患者肿瘤组织及A549细胞中的表达水平升高,可作为LUAD进展及预后的分子标志物。
Objective To investigate the expression of OTUD6B in lung adenocarcinoma(LUAD)tissue,and analyze its relationship with clinicopathological features and prognostic value.Methods The sequencing data and clinical information of LUAD patients were downloaded from the TCGA database to analyze the correlation between OTUD6B and clinicopathological characteristics of LUAD patients,and the differences in OS between the two groups with high and low expression of OTUD6B were compared by Kaplan-Meier method.Univariate and multifactorial Cox regression were used to analyze the independent prognostic factors affecting Overall survival(OS).The expression of OTUD6B in normal bronchial epithelial cell line BEAS-2B and human lung adenocarcinoma cell line A549 was detected by WB and RT-qPCR,and the effect of OTUD6B knockdown in A549 on cell proliferation was detected by CCK8.Results The expression of OTUD6B in lung adenocarcinoma tissue was significantly higher than that in adjacent normal tissue,with a statistically significant difference(t=13.056,P<0.001);And there was also a similar difference between paired cancer and adjacent tissues(t=2.744,P=0.008).There was no statistically significant difference in the expression of OTUD6B in tumor tissues of LUAD patients with different genders,ages,and smoking statuses(P>0.05);The expression level of OTUD6B in tumor tissues of stageⅢ-Ⅳpatients with pathological staging was significantly higher than that of stageⅠ-Ⅱpatients,and the difference was statistically significant(P<0.05).In terms of long-term prognosis,the median OS in the high expression group of OTUD6B was 42.39 months,significantly lower than 58.30 months in the low expression group,and the difference was statistically significant(HR=1.500,95%CI=1.124~2.003,P=0.006).The expression level of OTUD6B was an independent risk factor affecting patient OS(P=0.014).The expression levels of OTUD6B mRNA and protein in the A549 cell line were higher than those in BEAS-2B cells,and after knocking down OTUD6B in A549,the cell proli
作者
史玉峰
朱中成
贾晨飞
宋丽娜
王井润
SHI Yufeng;ZHU Zhongcheng;JIA Chenfei;SONG Lina;WANG Jingrun(Department of Radiotherapy,Cangzhou Central Hospital,Cangzhou,Hebei 061000,China)
出处
《临床肺科杂志》
2024年第9期1411-1416,共6页
Journal of Clinical Pulmonary Medicine
关键词
OTUD6B
肺腺癌
预后
临床病理特征
OTUD6B
Lung adenocarcinoma
Prognosis
Clinicopathological characteristics
